PRSU Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Buy PRSU now. The stock is in a clear bullish trend (stacked moving averages and expanding positive MACD), fundamentals just posted strong Q3 2025 growth, and Wall Street targets (low-$40s to high-$40s) imply meaningful upside from 35.47. With no negative news flow this week and supportive forward-demand commentary from analysts, the risk/reward favors buying immediately (even though price is near first resistance around 36.04).
Trend is bullish. SMA_5 > SMA_20 > SMA_200 confirms a strong uptrend across short/medium/long horizons. MACD histogram is +0.162 and expanding, signaling strengthening upside momentum. RSI_6 at ~64.3 is constructive (not yet overbought), consistent with a continuation setup rather than exhaustion. Key levels: support/pivot ~34.52 (near-term line in the sand) with S1 ~32.99; resistance R1 ~36.04 then R2 ~36.99. At 35.47, price is just below R1—break above ~36.04 would be a bullish continuation trigger; failure would likely mean a pullback toward ~34.5, but the broader setup remains positive.
Strong operating momentum: Q3 2025 revenue +32.24% YoY, net income +108.17% YoY, EPS +57.58% YoY, and gross margin improved—supports multiple expansion and/or higher targets.
Analyst commentary highlights encouraging early FY26 forward indicators across booking channels and high-barrier, iconic asset base.
Guidance momentum: Oppenheimer noted Q3 beat and raised full-year guidance (as of 2025-11-07), which often supports continued multiple strength.
Potential capital return/support: Stifel referenced buybacks and insider purchases signaling confidence (even though the provided insider-trend dataset reads neutral recently).
Near-term technical overhead: price is just below R1 (36.04); a failed breakout can trigger quick mean reversion toward the pivot (34.52).
FY26 'tough comp' narrative cited by analysts could create volatility around forward guidance updates.
Elevated implied volatility (IV30 ~75.
implies the market expects larger swings; if the next catalysts are merely “in-line,” the stock can chop despite good fundamentals.
No fresh news catalyst in the last week—near-term upside likely depends on technical breakout or future guidance/booking updates.
Latest reported quarter: 2025/Q3. Growth was strong and broad-based: Revenue rose to $241.0M (+32.24% YoY), Net Income to $73.85M (+108.17% YoY), EPS to $2.60 (+57.58% YoY). Profitability also improved with Gross Margin at 86.79% (+2.71% YoY). Overall, this is a high-quality quarter showing accelerating earnings power (net income growth outpacing revenue), which supports a bullish stance right now.
Recent analyst trend is positive with multiple upward price target revisions while maintaining bullish ratings. Stifel (Buy) raised PT to $42 (from $38 on 2025-11-06) and again to $44 (from $43 on 2025-12-10). Oppenheimer (Outperform) raised PT to $48 (from $45 on 2025-11-07) after Q3 beat and higher guidance. Wall Street pros: strong assets in iconic locations with barriers to entry, evidence of demand/booking strength, and improving financials. Cons: concern about tougher FY26 comparisons and potential volatility around forward guidance. Net: analyst stance is clearly supportive and skewed bullish.
